Business
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
Data from studies evaluating ibrexafungerp in serious fungal infections will be presented JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
About this update from Scynexis, Inc.
[{"type":"text","content":"Data from studies evaluating ibrexafungerp in serious fungal infections will be presented\nJERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data from its ongoing Phase 3 FURI and CARES studies, as well as multiple posters regarding studies of ibrexafungerp at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Lisbon, Portugal, April 23-26, 2022. “We are pleased to have this opportunity to share our most recent research analyses and hear updates from our colleagues regarding efforts by the global scientific community to treat serious infectious diseases,” said David Angulo, M.D., Chief Medical Officer, SCYNEXIS. “There are multiple exciting presentations and posters for this year’s meeting, and we are very excited to be attending in person again for the first time in two years.” Oral Presentation: Title: Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from Fourth Interim Analysis of a Phase 3 Open-label Study (FURI)2-Hour Oral Session 22. Emerging clinical data and interventional studies Presentation: O4797Date: April 25, 2022Time: 8:30 a.m. GMT/4:30 a.m. EDT Presenter: Martin Hoenigl, M.D., (Graz, Austria) Poster Presentations: Title: The FURI Study: Patient Outcomes After Treatment with Oral Ibrexafungerp Based on Prior Antifungal Therapy and Patient Enrollment CriteriaPoster Session 043: 6c. Antifungal drugs & treatment (incl clinical trials)Poster: P1550Presenter: Oliver Cornely, M.D. (Cologne, Germany) Title: Oral Ibrexafungerp Outcomes in Patients with Invasive Candidiasis and Candidemia from the FURI and CARES StudiesPoster Session: 043: 6c. Antifungal drugs & treatment (incl clinical trials)Poster: P1562Presenter: Oliver Cornely, M.D. (Cologne, Germany) Title: Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections from the CARES StudyPoster Session: 043: 6c. Antifungal drugs & treatment (incl clinical trials)Poster: L0246Presenter: R.S. Siebert (Pretoria, South Africa) Investigator-Initiated Studies with Ibrexafungerp Title: Efficacy assessment of ibrexafungerp in the neutropenic mouse model of pulmonary mucormycosisPoste...